Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults.


Journal

Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041

Informations de publication

Date de publication:
02 2020
Historique:
received: 02 09 2019
accepted: 05 11 2019
revised: 04 11 2019
pubmed: 17 11 2019
medline: 13 1 2021
entrez: 17 11 2019
Statut: ppublish

Résumé

Atypical teratoid/rhabdoid tumor (ATRT) is a highly malignant brain tumor predominantly occurring in infants. Mutations of the SMARCB1 gene are the characteristic genetic lesion. SMARCB1-mutant tumors in adolescents and adults are rare and may show uncommon histopathological and clinical features. Here we report seven SMARCB1-deficient intracranial tumors sharing distinct clinical, histopathological and molecular features. Median age of the four females and three males was 40 years (range 15-61 years). All tumors were located in the pineal region. Histopathologically, these tumors displayed spindled and epithelioid cells embedded in a desmoplastic stroma alternating with a variable extent of a loose myxoid matrix. All cases showed loss of nuclear SMARCB1/INI1 protein expression, expression of EMA and CD34 was frequent and the Ki67/MIB1 proliferation index was low in the majority of cases (median 3%). Three cases displayed heterozygous SMARCB1 deletions and two cases a homozygous SMARCB1 deletion. On sequencing, one tumor showed a 2 bp deletion in exon 4 (c.369_370del) and one a short duplication in exon 3 (c.237_276dup) both resulting in frameshift mutations. Most DNA methylation profiles were not classifiable using the Heidelberg Brain Tumor Classifier (version v11b4). By unsupervised t-SNE analysis and hierarchical clustering analysis, however, all tumors grouped closely together and showed similarities with ATRT-MYC. After a median observation period of 48 months, three patients were alive with stable disease, whereas one patient experienced tumor progression and three patients had succumbed to disease. In conclusion, our series represents an entity with distinct clinical, histopathological and molecular features showing epigenetic similarities with ATRT-MYC. We propose the designation desmoplastic myxoid tumor (DMT), SMARCB1-mutant, for these tumors.

Identifiants

pubmed: 31732806
doi: 10.1007/s00401-019-02094-w
pii: 10.1007/s00401-019-02094-w
doi:

Substances chimiques

SMARCB1 Protein 0
SMARCB1 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

277-286

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : HA 3060/8-1
Pays : International
Organisme : Deutsche Forschungsgemeinschaft
ID : TH 2345/1-1
Pays : International

Auteurs

Christian Thomas (C)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.

Annika Wefers (A)

Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Susanne Bens (S)

Institute of Human Genetics, University of Ulm and Ulm University Hospital, Ulm, Germany.

Karolina Nemes (K)

Swabian Childrens' Cancer Center, University Childrens' Hospital Augsburg and EU-RHAB Registry, Augsburg, Germany.

Abbas Agaimy (A)

Institute of Pathology, University of Erlangen, Erlangen, Germany.

Florian Oyen (F)

Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Silke Vogelgesang (S)

Institute of Pathology, Department of Neuropathology, University Medicine Greifswald, Greifswald, Germany.

Fausto J Rodriguez (FJ)

Department of Pathology, Johns Hopkins, Baltimore, MD, USA.

Francesca M Brett (FM)

Department of Neuropathology, Beaumont Hospital, Beaumont Road, Dublin, Ireland.

Roger McLendon (R)

Department of Pathology, Duke University, Durham, NC, USA.

Istvan Bodi (I)

Department of Clinical Neuropathology, King's College Hospital NHS Foundation Trust, London, UK.

Fanny Burel-Vandenbos (F)

Central Laboratory of Pathology, Nice University Hospital, Hôpital Pasteur, Nice, France.

Kathy Keyvani (K)

Institute of Neuropathology, University of Duisburg-Essen, Essen, Germany.

Stefan Tippelt (S)

Department of Pediatric Oncology and Hematology, Pediatrics III, University Hospital Essen, Essen, Germany.

Frantz R Poulsen (FR)

Department of Neurosurgery, Odense University Hospital, Odense, Denmark.

Eric S Lipp (ES)

Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.

Caterina Giannini (C)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Guido Reifenberger (G)

Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany.
German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, German Cancer Research Center (DKFZ), Düsseldorf, Germany.

Klaus Kuchelmeister (K)

Institute of Neuropathology and DGNN Brain Tumor Reference Centre, University of Bonn, Bonn, Germany.

Torsten Pietsch (T)

Institute of Neuropathology and DGNN Brain Tumor Reference Centre, University of Bonn, Bonn, Germany.

Uwe Kordes (U)

Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Reiner Siebert (R)

Institute of Human Genetics, University of Ulm and Ulm University Hospital, Ulm, Germany.

Michael C Frühwald (MC)

Swabian Childrens' Cancer Center, University Childrens' Hospital Augsburg and EU-RHAB Registry, Augsburg, Germany.

Pascal D Johann (PD)

Hopp-Children's Cancer Center (KiTZ), Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.

Martin Sill (M)

Hopp-Children's Cancer Center (KiTZ), Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.

Marcel Kool (M)

Hopp-Children's Cancer Center (KiTZ), Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.

Andreas von Deimling (A)

Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Werner Paulus (W)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany.

Martin Hasselblatt (M)

Institute of Neuropathology, University Hospital Münster, Pottkamp 2, Münster, Germany. hasselblatt@uni-muenster.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH